{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:50:28Z","timestamp":1791654628040,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.josat.2026.210099","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:49:34Z","timestamp":1787701774000},"page":"210099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patient preferences for medications to treat opioid use disorder in carceral settings: Implications for tailored implementation and service delivery"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9006-6262","authenticated-orcid":false,"given":"Amelia","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn M.W.","family":"Hughto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.A.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira I.","family":"Dunsiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2026.210099_bb0005","author":"American Society of Addiction Medicine"},{"key":"10.1016\/j.josat.2026.210099_bb0010","author":"American Society of Addiction Medicine"},{"issue":"6","key":"10.1016\/j.josat.2026.210099_bb0015","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/104973230201200611","article-title":"Matrix analysis as a complementary analytic strategy in qualitative inquiry","volume":"12","author":"Averill","year":"2002","journal-title":"Qualitative Health Research"},{"key":"10.1016\/j.josat.2026.210099_bb0020","series-title":"Data for: Use of medications to treat opioid use disorder during incarceration and upon release: A mixed methods study and review of influential social-ecological factors version DRAFT VERSION [coded qualitative interview data]","author":"Bailey","year":"2026"},{"key":"10.1016\/j.josat.2026.210099_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2025.100395","article-title":"Multilevel determinants of medication preferences for opioid use disorder among criminal-legal-involved populations: Insights from a scoping review","volume":"17","author":"Bailey","year":"2025","journal-title":"Drug and Alcohol Dependence Reports"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0030","doi-asserted-by":"crossref","DOI":"10.1007\/s40429-025-00701-3","article-title":"Rapid inpatient methadone induction in the fentanyl era: A systematic review of safety, efficacy, and protocols for hospitalized patients with opioid use disorder","volume":"13","author":"Berisha","year":"2026","journal-title":"Current Addiction Reports"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40352-025-00317-9","article-title":"Medication for opioid use disorder service delivery in carceral facilities: Update and summary report","volume":"13","author":"Berk","year":"2025","journal-title":"Health & Justice"},{"issue":"9","key":"10.1016\/j.josat.2026.210099_bb0040","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-159-9-201311050-00005","article-title":"Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009","volume":"159","author":"Binswanger","year":"2013","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0045","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/1744987107081254","article-title":"Memoing in qualitative research: Probing data and processes","volume":"13","author":"Birks","year":"2008","journal-title":"Journal of Research in Nursing"},{"issue":"2","key":"10.1016\/j.josat.2026.210099_bb0050","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qualitative Research in Psychology"},{"issue":"3","key":"10.1016\/j.josat.2026.210099_bb0055","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/14780887.2020.1769238","article-title":"One size fits all? What counts as quality practice in (reflexive) thematic analysis?","volume":"18","author":"Braun","year":"2021","journal-title":"Qualitative Research in Psychology"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/26895269.2022.2129597","article-title":"Toward good practice in thematic analysis: Avoiding common problems and be(com)ing a knowing researcher","volume":"24","author":"Braun","year":"2023","journal-title":"International Journal of Transgender Health"},{"issue":"7","key":"10.1016\/j.josat.2026.210099_bb0065","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1037\/0003-066X.32.7.513","article-title":"Toward an experimental ecology of human development","volume":"32","author":"Bronfenbrenner","year":"1977","journal-title":"American Psychologist"},{"issue":"2","key":"10.1016\/j.josat.2026.210099_bb0070","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/14780887.2014.955224","article-title":"The utility of template analysis in qualitative psychology research","volume":"12","author":"Brooks","year":"2015","journal-title":"Qualitative Research in Psychology"},{"key":"10.1016\/j.josat.2026.210099_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108832","article-title":"Adapting methadone inductions to the fentanyl era","volume":"141","author":"Buresh","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.josat.2026.210099_bb0080","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/29767342251326339","article-title":"Medications for opioid use disorder: Patients\u2019 experience, knowledge, and preferences in the era of illicitly manufactured fentanyl","volume":"46","author":"Casey","year":"2025","journal-title":"Subst Use Addctn J"},{"issue":"4","key":"10.1016\/j.josat.2026.210099_bb0085","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1016\/j.josat.2026.210099_bb0090","series-title":"Doing qualitative research","first-page":"163","article-title":"Using codes and code manuals: A template organizing style of interpretation","volume":"2nd ed","author":"Crabtree","year":"1999"},{"issue":"6","key":"10.1016\/j.josat.2026.210099_bb0095","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: A systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.josat.2026.210099_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104252","article-title":"Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts [article]","volume":"122","author":"Evans","year":"2023","journal-title":"International Journal of Drug Policy"},{"key":"10.1016\/j.josat.2026.210099_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108746","article-title":"Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail","volume":"138","author":"Evans","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2026.210099_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109254","article-title":"Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder","volume":"231","author":"Evans","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.josat.2026.210099_bb0115","doi-asserted-by":"crossref","first-page":"e255340","DOI":"10.1001\/jamanetworkopen.2025.5340","article-title":"Barriers to universal availability of medications for opioid use disorder in US jails","volume":"8","author":"Flanagan Balawajder","year":"2025","journal-title":"JAMA Network Open"},{"issue":"16","key":"10.1016\/j.josat.2026.210099_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19169954","article-title":"Burnout among professionals working in corrections: A two stage review","volume":"19","author":"Forman-Dolan","year":"2022","journal-title":"International Journal of Environmental Research and Public Health"},{"key":"10.1016\/j.josat.2026.210099_bb0125","article-title":"\u201cI still can feel the sickness\u201d: Withdrawal experiences of people on methadone maintenance treatment","volume":"170","author":"Frank","year":"2025","journal-title":"J Subst Use Addict Treat"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-023-00893-9","article-title":"\u201cAs safe as possible\u201d: A qualitative study of opioid withdrawal and risk behavior among people who use illegal opioids [article]","volume":"20","author":"Frank","year":"2023","journal-title":"Harm Reduction Journal"},{"issue":"10","key":"10.1016\/j.josat.2026.210099_bb0135","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMsa2415987","article-title":"Medications for opioid use disorder in county jails \u2014 Outcomes after release","volume":"393","author":"Friedmann","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.josat.2026.210099_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102768","article-title":"A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system","volume":"81","author":"Grella","year":"2020","journal-title":"The International Journal on Drug Policy"},{"issue":"5","key":"10.1016\/j.josat.2026.210099_bb0145","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1080\/00952990.2025.2528778","article-title":"Perceived stigma and its role in substance use disorder treatment completion","volume":"51","author":"Isman","year":"2025","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0150","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12961-020-00596-8","article-title":"The opioid crisis: A contextual, social-ecological framework","volume":"18","author":"Jalali","year":"2020","journal-title":"Health Res Policy Syst"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0155","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/ADM.0000000000001029","article-title":"Anticipated barriers to sustained engagement in treatment with medications for opioid use disorder after release from incarceration","volume":"17","author":"Kaplowitz","year":"2023","journal-title":"Journal of Addiction Medicine"},{"issue":"4","key":"10.1016\/j.josat.2026.210099_bb0160","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1108\/IJPH-04-2020-0020","article-title":"A social ecological model (SEM) to exploring barriers of and facilitators to the implementation of opioid agonist treatment (OAT) programmes in prisons","volume":"17","author":"Komalasari","year":"2021","journal-title":"International Journal of Prisoner Health"},{"key":"10.1016\/j.josat.2026.210099_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111377","article-title":"Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study","volume":"261","author":"Krawczyk","year":"2024","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.josat.2026.210099_bb0170","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","article-title":"Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: Implications for policy","volume":"8","author":"Krawczyk","year":"2023","journal-title":"The Lancet Public Health"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0175","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1186\/s12889-025-24935-y","article-title":"Using the socioecological model to guide service delivery improvements to the prison needle exchange program in Canada: Insights from multi-level stakeholders","volume":"25","author":"Kronfli","year":"2025","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.josat.2026.210099_bb0180","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/add.16071","article-title":"Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from new York City jails 2011-17","volume":"118","author":"Lim","year":"2023","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2026.210099_bb0185","author":"Lumivero"},{"key":"10.1016\/j.josat.2026.210099_bb0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.josat.2023.209066","article-title":"Perceived access to opioid agonist treatment in prison among people with a history of injection drug use: A qualitative study","volume":"150","author":"Marshall","year":"2023","journal-title":"Journal of Substance use & Addiction Treatment"},{"key":"10.1016\/j.josat.2026.210099_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2022.100419","article-title":"Post-incarceration outcomes of a comprehensive statewide correctional MOUD program: A retrospective cohort study","volume":"18","author":"Martin","year":"2023","journal-title":"The Lancet Regional Health-Americas"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0200","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12954-025-01291-z","article-title":"A mixed-method exploratory assessment of provider-based stigma of opioid use disorder (OUD) and support for medications for opioid use disorder (MOUD) in carceral settings","volume":"22","author":"McLean","year":"2025","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.josat.2026.210099_bb0205","series-title":"Qualitative data analysis: A methods sourcebook","author":"Miles","year":"2020"},{"key":"10.1016\/j.josat.2026.210099_bb0210","series-title":"Medications for opioid use disorder save lives","author":"National Academies of Sciences, E., & Medicine","year":"2019"},{"key":"10.1016\/j.josat.2026.210099_bb0215","author":"National Commission on Correctional Health Care"},{"key":"10.1016\/j.josat.2026.210099_bb0220","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2026.210099_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2023.100211","article-title":"The association between attitudes and the provision of medications for opioid use disorder (MOUD) in United States jails","volume":"10","author":"Pfaff","year":"2024","journal-title":"Drug and Alcohol Dependence Reports"},{"key":"10.1016\/j.josat.2026.210099_bb0230","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.drugalcdep.2018.04.034","article-title":"Beyond the walls: Risk factors for overdose mortality following release from the Philadelphia Department of Prisons","volume":"189","author":"Pizzicato","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2026.210099_bb0235","author":"Prescott"},{"issue":"9","key":"10.1016\/j.josat.2026.210099_bb0240","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/journalofethics.2017.19.9.ecas4-1709","article-title":"What does health justice look like for people returning from incarceration?","volume":"19","author":"Puglisi","year":"2017","journal-title":"AMA Journal of Ethics"},{"key":"10.1016\/j.josat.2026.210099_bb0245","author":"rev.com"},{"issue":"3","key":"10.1016\/j.josat.2026.210099_bb0250","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/jurban\/jti072","article-title":"Attitudes and practices regarding the use of methadone in US state and federal prisons","volume":"82","author":"Rich","year":"2005","journal-title":"Journal of Urban Health"},{"key":"10.1016\/j.josat.2026.210099_bb0255","series-title":"Qualitative interviewing: The art of hearing data","author":"Rubin","year":"2012"},{"key":"10.1016\/j.josat.2026.210099_bb0260","doi-asserted-by":"crossref","DOI":"10.17269\/s41997-026-01186-x","article-title":"Clarifying the evidence and implications of prioritizing extended-release buprenorphine for opioid agonist treatment in Canada\u2019s federal correctional system","author":"Russell","year":"2026","journal-title":"Canadian Journal of Public Health"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0265","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-022-12685-0","article-title":"Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: A mixed-methods study [article]","volume":"22","author":"Russell","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.josat.2026.210099_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ssmqr.2022.100083","article-title":"Applying the socio-ecological model to understand community reintegration experiences among individuals on opioid agonist treatment (OAT) released from federal incarceration in Ontario, Canada","volume":"2","author":"Russell","year":"2022","journal-title":"SSM-Qualitative Research in Health"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0275","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40352-025-00319-7","article-title":"Patient perspectives of jail based MOUD treatment: Views of individuals who have returned to the community following incarceration","volume":"13","author":"Santelices","year":"2025","journal-title":"Health Justice"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0280","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40352-021-00143-9","article-title":"The impact of the opioid crisis on U.S. state prison systems","volume":"9","author":"Scott","year":"2021","journal-title":"Health Justice"},{"key":"10.1016\/j.josat.2026.210099_bb0285","series-title":"Stata Statistical Software: Release 19","author":"StataCorp","year":"2025"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0290","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13722-024-00486-2","article-title":"Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: A qualitative study","volume":"19","author":"Stopka","year":"2024","journal-title":"Addiction Science & Clinical Practice"},{"issue":"1","key":"10.1016\/j.josat.2026.210099_bb0295","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nature Reviews. Disease Primers"},{"issue":"6","key":"10.1016\/j.josat.2026.210099_bb0300","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/add.70002","article-title":"The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021","volume":"120","author":"Stringfellow","year":"2025","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.josat.2026.210099_bb0305","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups","volume":"19","author":"Tong","year":"2007","journal-title":"International Journal for Quality in Health Care"},{"key":"10.1016\/j.josat.2026.210099_bb0310","doi-asserted-by":"crossref","first-page":"357","DOI":"10.12688\/f1000research.23640.3","article-title":"Access to treatment in prison: An inventory of medication preparation and distribution approaches","volume":"9","author":"Tran","year":"2020","journal-title":"F1000Res"},{"key":"10.1016\/j.josat.2026.210099_bb0315","series-title":"Qualitative methods in public health: A field guide for applied research","author":"Ulin","year":"2012"},{"key":"10.1016\/j.josat.2026.210099_bb0320","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","article-title":"Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis","volume":"160","author":"Yarborough","year":"2016","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926002195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926002195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:32:34Z","timestamp":1791653554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875926002195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":64,"alternative-id":["S2949875926002195"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2026.210099","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient preferences for medications to treat opioid use disorder in carceral settings: Implications for tailored implementation and service delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2026.210099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"210099"}}